{"id":64360,"date":"2026-04-30T22:29:56","date_gmt":"2026-04-30T14:29:56","guid":{"rendered":"https:\/\/flcube.com\/?p=64360"},"modified":"2026-04-30T22:29:58","modified_gmt":"2026-04-30T14:29:58","slug":"astrazeneca-reports-8-q1-revenue-growth-to-15-3b-driven-by-oncology-and-rare-disease-strength","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64360","title":{"rendered":"AstraZeneca Reports 8% Q1 Revenue Growth to $15.3B Driven by Oncology and Rare Disease Strength"},"content":{"rendered":"\n

AstraZeneca PLC<\/strong> (NYSE: AZN<\/a>) reported first-quarter 2026 financial results<\/strong> with total revenue of USD 15.288 billion<\/strong>, representing 8% year-over-year (YOY) growth<\/strong>. The performance was primarily driven by double-digit growth in Oncology (+16%) and Rare Disease (+15%) divisions<\/strong>, offsetting a slight decline in Biopharmaceuticals (-2%) and cardiovascular headwinds from China’s volume-based procurement implementation.<\/p>\n\n\n\n

Financial Highlights \u2013 Q1 2026<\/h2>\n\n\n\n
Metric<\/th>Q1 2026<\/th>YOY Change<\/th><\/tr><\/thead>
Total Revenue<\/strong><\/td>USD 15.288 billion<\/td>+8%<\/td><\/tr>
Product Sales<\/strong><\/td>USD 15.211 billion<\/td>+8%<\/td><\/tr>
Oncology Division<\/strong><\/td>USD 6.797 billion<\/td>+16%<\/td><\/tr>
Biopharmaceuticals<\/strong><\/td>USD 5.741 billion<\/td>-2%<\/td><\/tr>
Rare Disease<\/strong><\/td>USD 2.420 billion<\/td>+15%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Geographic Performance<\/h2>\n\n\n\n
Region<\/th>Q1 2026 Sales<\/th>YOY Change<\/th><\/tr><\/thead>
United States<\/strong><\/td>USD 6.204 billion<\/td>+10%<\/td><\/tr>
Europe<\/strong><\/td>USD 3.405 billion<\/td>+9%<\/td><\/tr>
Emerging Markets (ex-China)<\/strong><\/td>USD 2.475 billion<\/td>+9%<\/td><\/tr>
China<\/strong><\/td>USD 1.923 billion<\/td>+2%<\/td><\/tr>
Established Rest of World (ERoW)<\/strong><\/td>USD 1.204 billion<\/td>+2%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Oncology Portfolio Breakdown<\/h2>\n\n\n\n
Product<\/th>Q1 2026 Sales<\/th>YOY Change<\/th>Key Dynamics<\/th><\/tr><\/thead>
Tagrisso (osimertinib)<\/strong><\/td>USD 1.833 billion<\/td>+5%<\/td>Strong demand across multiple indications maintains market leadership<\/td><\/tr>
Imfinzi (durvalumab)<\/strong><\/td>USD 1.694 billion<\/td>+30%<\/td>Exceptional growth driven by expanding indications in lung cancer and other solid tumors<\/td><\/tr>
Enhertu (trastuzumab deruxtecan)<\/strong><\/td>USD 1.422 billion<\/td>+34%<\/td>Co-developed with Daiichi Sankyo; rapid adoption across HER2-positive cancers<\/td><\/tr>
Calquence (acalabrutinib)<\/strong><\/td>USD 0.923 billion<\/td>+17%<\/td>Maintains BTK inhibitor leadership in first-line chronic lymphocytic leukemia<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Other Therapeutic Areas<\/h2>\n\n\n\n

Cardiovascular<\/h3>\n\n\n\n